CoDiagnostics (CODX) Upgraded to Buy: Here's What You Should Know

Core Insights - Co-Diagnostics, Inc. (CODX) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3] - The Zacks rating system is based on changes in earnings estimates, providing a more objective measure for investors compared to traditional Wall Street ratings [2][9] Earnings Estimates and Stock Performance - The correlation between changes in earnings estimates and stock price movements is strong, influenced by institutional investors who adjust their valuations based on these estimates [4][5] - CoDiagnostics is expected to earn -$0.72 per share for the fiscal year ending December 2025, with no year-over-year change, but the Zacks Consensus Estimate has increased by 8.9% over the past three months [8] Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7] - The upgrade of CoDiagnostics to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]